ISRCTN48265228未知未知
A novel brain-based therapy for attention deficit hyperactivity disorder children using transcranial direct current stimulation combined with cognitive training
试验速览
- 阶段
- 未知
- 入组人数
- 50
研究概览
简要总结
2021 results in https://pubmed.ncbi.nlm.nih.gov/34225830/ (added 07/07/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •Updated 12/05/2020: current inclusion criteria since ethics approval on 18/07/2017:
- •1. Age range: 10-18 years
- •2. Gender: male
- •3. Meeting DSM-5 diagnosis of ADHD
- •4. Score above clinical cut-off on the Schedule for Affective Disorders and Schizophrenia, ADHD module (K-SADS)
- •5. Score about clinical cut-off for ADHD on the short forms of the Conners Parent Rating Scales (CPRS)
- •6. Patients will be either medication naïve or on their usual stable medication without change in regime throughout the study
- •7. IQ > 80 as tested on the 4 subtests of the WASI (Wechsler, 1999) that assesses intellectual ability of individuals aged 6 years and over. Administration of 4 subtests takes ~ 40 minutes, and produces a full-scale IQ score
- •Comorbidity with other disorder will be allowed except the ones outlined below under exclusion criteria
- •Previous inclusion criteria:
- •1. Age range: 10-17 years
- •2. Gender: male
- •3. Meeting DSM-5 diagnosis of ADHD
- •4. Score above clinical cut-off on the Schedule for Affective Disorders and Schizophrenia, ADHD module (K-SADS)
- •5. Score about clinical cut-off for ADHD on the short forms of the Conners Parent and Teacher Rating Scales (CPRS/CTRS)
- •6. Patients will be either medication naïve or on their usual stable medication without change in regime throughout the study
- •7. IQ > 80 as tested on the 4 subtests of the WASI (Wechsler, 1999) that assesses intellectual ability of individuals aged 6 years and over. Administration of 4 subtests takes ~ 40 minutes, and produces a full-scale IQ score
- •Comorbidity with other disorder will be allowed except the ones outlined below under exclusion criteria
排除标准
- •1. IQ < 80
- •2. Comorbidity with schizophrenia, Bipolar disorder, learning disability, severe depression with current suicidal behaviour (as assessed by clinician)
- •3. Neurological problems, i.e. a history of severe neurological illness, e.g. brain tumour, epilepsy or a history of symptomatic seizures, polyneuropathy etc
- •4. Substance abuse history
- •5. Contraindication to neurostimulation. i.e., previous implantation of metallic material (e.g., vascular clips, cochlear implant) in the cranium (except in the mouth), pacemaker, implanted medication pumps, neural stimulators
- •6. Drug treatment acting primarily on the central nervous system which lowers the seizure threshold such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants
- •7. Diseased or damaged skin over the face or scalp
- •8. History of migraine (brain stimulation may increase susceptibility to headaches in migraineurs)
- •9. Unable to give informed assent or consent in the case of the primary caregiver
研究者
相似试验
已完成
2 期
oninvasive brain stimulation for attention deficits after traumatic brain injuryAttention deficits after traumatic brain injuryInjury, Occupational Diseases, PoisoningISRCTN55243064Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal6
招募中
不适用
Investigating brain mechanisms and new treatment modalities for persistent postural-perceptual dizziness (PPPD)Diseases of the nervous systemKCT0005068The Catholic University of Korea, Incheon St. Mary's Hospital60
Unknown
2 期
Neurofeedback Study ADHDADHDNCT01879644Philipps University Marburg Medical Center120
已完成
不适用
Does the treatment of maternal Attention Deficit Hyperactivity Disorder enhance the effectiveness of parent management training for children's attention deficit hyperactivity disorder?ISRCTN73911400Wuerzburg University Hospital (Germany)144
已完成
4 期
Can treatment with N-PEP-12 improve recovery after acute ischemic stroke?Supratentorial, radiologically confirmed ischemic stroke with the onset 30-120 days prior to screeningCirculatory SystemISRCTN10702895EN: The foundation for the study of neuroscience and neuroregeneration (RO: Fundatia pentru Studiul Nanoneurostiintelor si Neuroregenerarii)121